去纤苷在中国批准上市了吗？

Defibrotide (defiteli) is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). It was approved for marketing in the European Union in October 2013, and was approved for marketing in the United States by the U.S. Food and Drug Administration (FDA) on March 30, 2016, under the trade name Defitelio.

For some patients with leukemia and lymphoma, hematopoietic stem cell transplantation (HSCT) is the only hope to cure the disease and regain health. Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide (defiteli, produced in Italy) is a mixture of single-stranded oligonucleotides with antithrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide (defiteli) is a safe and effective drug for preventing and treating HVOD.

Many patients will ask whether defibrotide has been approved for marketing in China?

Currently, defibrotide (defiteli) is not on the market in mainland China. It can be purchased in some pharmacies in Hong Kong, and the price is basically the same as the international price. Patients can go to countries such as the United States to buy medicines on their own, or they can go to regular pharmacies in Hong Kong to buy medicines. Never buy medicines through informal channels for cheap. If it is inconvenient for the patient to travel far, he or she can also consult a reliable domestic overseas medical consulting service company (such as Medical Companion Travel) for purchase.

In clinical trials, defibrotide (defiteli) can very well prevent the occurrence of HVOD. It can not only be used to treat adults, but children can also benefit from it. Moreover, when defibrotide is combined with heparin, the incidence of side effects is very low and the safety is relatively high. Defibrotide has also been granted "orphan drug" designation by the FDA.